首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1094950

全球免疫球蛋白市场：未来预测（2022-2030）

Global Immunoglobulin Market Forecast 2022-2030

出版日期: 2022年07月04日 | 出版商:

Inkwood Research | 英文 235 Pages | 商品交期: 2-3个工作天内

价格

简介目录图表

在预测期间（2022-2030 年），全球免疫球蛋白市场预计将以 6.87% 的复合年增长率增长。主要的市场驱动因素包括自身免疫和免疫缺陷疾病发病率的增加、老年人口的增加以及研发（R&D）活动的□□增加。

按地区划分，预计亚太地区增长最快。

本报告分析了全球免疫球蛋白市场，包括主要促进剂/抑製剂、市场规模趋势（过去 3 年/未来 9 年）、细分市场和地区的详细趋势以及竞争。我们正在调查情况，概况主要公司（公司简介、主要产品/服务、SCOT 分析、业务战略等）。

重大战略发展趋势
- 併购（併购）
- 产品发布和开发
- 商业联盟、合同
- 业务扩展/销售
公司简介
- ADMA BIOLOGICS
- BIO PRODUCTS LABORATORY
- BIOTEST AG
- CHINA BIOLOGIC PRODUCTS INC
- CSL BEHRING
- GRIFOLS SA
- KAMADA LTD
- KEDRION BIOPHARMA
- LFB GROUP
- OCTAPHARMA AG
- PFIZER INC
- SANQUIN PLASMA PRODUCTS BV
- SHANGHAI RAAS BLOOD PRODUCTS CO LTD
- SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
- TAKEDA PHARMACEUTICAL COMPANY LIMITED

简介目录图表

Product Code: 46421

KEY FINDINGS

The global immunoglobulin market is anticipated to rise with a CAGR of 6.87% across the forecast years of 2022 to 2030. The market's growth is strengthened by the increasing incidence of autoimmune disorders as well as immunodeficiency diseases, the rise in the geriatric populace, and the growing research and development activities.

MARKET INSIGHTS

Immunoglobulins are characterized as antibodies that are produced naturally by the body's immune system. They primarily help fight diseases and infections. These glycoprotein molecules are generated by plasma cells and also act as a pivotal component of the immune response of the body.

The rise in the geriatric population across the world is a leading factor expected to fuel the global immunoglobulin market growth over the forecasted years. As an individual ages, their immune system tends to deteriorate and responds relatively slower. This factor significantly increases the risk of sickness.

Moreover, the loss of adaptive immunity entailing older age not only makes a person more vulnerable to infections but also reactivates dormant pathogens that were formerly suppressed. As a result, the senior population is at a higher risk of an increased incidence of immunodeficiency diseases as well as the severity of certain infections. Hence, the growth in the elderly is set to augment the prevalence of age-related diseases, subsequently increasing the need for immunoglobulin products for their treatment.

REGIONAL INSIGHTS

The global immunoglobulin market growth assessment comprises the evaluation of North America, Europe, Asia-Pacific, and Rest of World. The Asia-Pacific is expected to be the fastest-growing region during the forecast years. The regional market's growth is mainly ascribed to the surging prevalence of different types of diseases, the increasing elderly population, and the surge in research and development.

COMPETITIVE INSIGHTS

The competitive rivalry within the global immunoglobulin market is intense and is anticipated to remain high during the forecast period. Furthermore, the presence of numerous leading market players across various regions facilitates a higher level of competition since the industry is fragmented. Some of the key players operating in the market are Pfizer Inc, Kamada Ltd, LFB Group, etc.

Our report offerings include:

Explore key findings of the overall market

Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

Market Segmentation cater to a thorough assessment of key segments with their market estimations

Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. GROWTH IN GERIATRIC POPULATION
- 3.1.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
- 3.1.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
3.2. KEY RESTRAINTS
- 3.2.1. HIGH COST OF THERAPY
- 3.2.2. HIGH RISK OF SIDE EFFECTS

4. KEY ANALYTICS

4.1. IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY BUYING CRITERIA
- 4.6.1. SOURCE
- 4.6.2. APPLICATION
- 4.6.3. EPITOPE
- 4.6.4. VALIDATION
4.7. REGULATORY FRAMEWORK

5. MARKET BY PRODUCT

5.1. IGG
5.2. IGA
5.3. IGM
5.4. IGE
5.5. IGD

6. MARKET BY MODE OF DELIVERY

6.1. INTRAVENOUS IMMUNOGLOBULIN
6.2. SUBCUTANEOUS IMMUNOGLOBULIN
6.3. INTRAMUSCULAR IMMUNOGLOBULIN

7. MARKET BY APPLICATION

7.1. HYPOGAMMA GLOBULINEMIA
7.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
7.3. PRIMARY IMMUNODEFICIENCY DISEASES
7.4. MYASTHENIA GRAVIS
7.5. MULTIFOCAL MOTOR NEUROPATHY
7.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
7.7. INFLAMMATORY MYOPATHIES
7.8. SPECIFIC ANTIBODY DEFICIENCY
7.9. GUILLAIN-BARRE SYNDROME
7.10. OTHER APPLICATIONS

8. MARKET BY DISTRIBUTION CHANNEL

8.1. HOSPITAL PHARMACY
8.2. SPECIALTY PHARMACY
8.3. OTHER DISTRIBUTION CHANNELS

9. MARKET BY END-USER

9.1. HOSPITALS & CLINICS
9.2. HOMECARE

10. GEOGRAPHICAL ANALYSIS

10.1. NORTH AMERICA
- 10.1.1. MARKET SIZE & ESTIMATES
- 10.1.2. KEY GROWTH ENABLERS
- 10.1.3. KEY CHALLENGES
- 10.1.4. KEY PLAYERS
- 10.1.5. COUNTRY ANALYSIS
  - 10.1.5.1. UNITED STATES
  - 10.1.5.2. CANADA
10.2. EUROPE
- 10.2.1. MARKET SIZE & ESTIMATES
- 10.2.2. KEY GROWTH ENABLERS
- 10.2.3. KEY CHALLENGES
- 10.2.4. KEY PLAYERS
- 10.2.5. COUNTRY ANALYSIS
  - 10.2.5.1. UNITED KINGDOM
  - 10.2.5.2. GERMANY
  - 10.2.5.3. FRANCE
  - 10.2.5.4. SPAIN
  - 10.2.5.5. ITALY
  - 10.2.5.6. NORDIC COUNTRIES
  - 10.2.5.7. REST OF EUROPE
10.3. ASIA-PACIFIC
- 10.3.1. MARKET SIZE & ESTIMATES
- 10.3.2. KEY GROWTH ENABLERS
- 10.3.3. KEY CHALLENGES
- 10.3.4. KEY PLAYERS
- 10.3.5. COUNTRY ANALYSIS
  - 10.3.5.1. CHINA
  - 10.3.5.2. JAPAN
  - 10.3.5.3. INDIA
  - 10.3.5.4. SOUTH KOREA
  - 10.3.5.5. INDONESIA
  - 10.3.5.6. THAILAND
  - 10.3.5.7. VIETNAM
  - 10.3.5.8. AUSTRALIA
  - 10.3.5.9. REST OF ASIA-PACIFIC
10.4. REST OF WORLD
- 10.4.1. MARKET SIZE & ESTIMATES
- 10.4.2. KEY GROWTH ENABLERS
- 10.4.3. KEY CHALLENGES
- 10.4.4. KEY PLAYERS
- 10.4.5. REGIONAL ANALYSIS
  - 10.4.5.1. LATIN AMERICA
  - 10.4.5.2. MIDDLE EAST & AFRICA

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS
- 11.1.1. MERGERS & ACQUISITIONS
- 11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 11.1.3. PARTNERSHIPS & AGREEMENTS
- 11.1.4. BUSINESS EXPANSIONS & DIVESTITURES
11.2. COMPANY PROFILES
- 11.2.1. ADMA BIOLOGICS
- 11.2.2. BIO PRODUCTS LABORATORY
- 11.2.3. BIOTEST AG
- 11.2.4. CHINA BIOLOGIC PRODUCTS INC
- 11.2.5. CSL BEHRING
- 11.2.6. GRIFOLS SA
- 11.2.7. KAMADA LTD
- 11.2.8. KEDRION BIOPHARMA
- 11.2.9. LFB GROUP
- 11.2.10. OCTAPHARMA AG
- 11.2.11. PFIZER INC
- 11.2.12. SANQUIN PLASMA PRODUCTS BV
- 11.2.13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD
- 11.2.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
- 11.2.15. TAKEDA PHARMACEUTICAL COMPANY LIMITED

简介目录图表

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - IMMUNOGLOBULIN
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: GLOBAL IMMUNOGLOBULIN MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 4: GLOBAL IMMUNOGLOBULIN MARKET, BY PRODUCT, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 5: GLOBAL IGG MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 6: GLOBAL IGG MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 7: GLOBAL IGA MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 8: GLOBAL IGA MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 9: GLOBAL IGM MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 10: GLOBAL IGM MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 11: GLOBAL IGE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 12: GLOBAL IGE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 13: GLOBAL IGD MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 14: GLOBAL IGD MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 16: GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 17: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 18: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 19: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 20: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 21: GLOBAL INTRAMUSCULAR IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 22: GLOBAL INTRAMUSCULAR IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 23: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 24: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 25: GLOBAL HYPOGAMMA GLOBULINEMIA MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 26: GLOBAL HYPOGAMMA GLOBULINEMIA MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 27: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 28: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 29: GLOBAL PRIMARY IMMUNODEFICIENCY DISEASES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 30: GLOBAL PRIMARY IMMUNODEFICIENCY DISEASES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 31: GLOBAL MYASTHENIA GRAVIS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 32: GLOBAL MYASTHENIA GRAVIS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 33: GLOBAL MULTIFOCAL MOTOR NEUROPATHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 34: GLOBAL MULTIFOCAL MOTOR NEUROPATHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 35: GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 36: GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 37: GLOBAL INFLAMMATORY MYOPATHIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 38: GLOBAL INFLAMMATORY MYOPATHIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 39: GLOBAL SPECIFIC ANTIBODY DEFICIENCY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 40: GLOBAL SPECIFIC ANTIBODY DEFICIENCY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 41: GLOBAL GUILLAIN-BARRE SYNDROME MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 42: GLOBAL GUILLAIN-BARRE SYNDROME MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 43: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 44: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 45: GLOBAL IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 46: GLOBAL IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 47: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 48: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 49: GLOBAL SPECIALTY PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 50: GLOBAL SPECIALTY PHARMACY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 51: GLOBAL OTHER DISTRIBUTION CHANNELS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 52: GLOBAL OTHER DISTRIBUTION CHANNELS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 53: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 54: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 55: GLOBAL HOSPITALS & CLINICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 56: GLOBAL HOSPITALS & CLINICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 57: GLOBAL HOMECARE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 58: GLOBAL HOMECARE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 59: GLOBAL IMMUNOGLOBULIN MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 60: GLOBAL IMMUNOGLOBULIN MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 61: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 62: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 63: LEADING PLAYERS OPERATING IN NORTH AMERICA IMMUNOGLOBULIN MARKET
TABLE 64: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 65: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 66: LEADING PLAYERS OPERATING IN EUROPE IMMUNOGLOBULIN MARKET
TABLE 67: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 68: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 69: LEADING PLAYERS OPERATING IN ASIA-PACIFIC IMMUNOGLOBULIN MARKET
TABLE 70: REST OF WORLD IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 71: REST OF WORLD IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 72: LEADING PLAYERS OPERATING IN REST OF WORLD IMMUNOGLOBULIN MARKET
TABLE 73: LIST OF MERGERS & ACQUISITIONS
TABLE 74: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 75: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 76: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: OPPORTUNITY MATRIX
FIGURE 4: VENDOR LANDSCAPE
FIGURE 5: KEY BUYING CRITERIA
FIGURE 6: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021
FIGURE 7: GLOBAL IMMUNOGLOBULIN MARKET, BY IGG, 2022-2030 (IN $ MILLION)
FIGURE 8: GLOBAL IMMUNOGLOBULIN MARKET, BY IGA, 2022-2030 (IN $ MILLION)
FIGURE 9: GLOBAL IMMUNOGLOBULIN MARKET, BY IGM, 2022-2030 (IN $ MILLION)
FIGURE 10: GLOBAL IMMUNOGLOBULIN MARKET, BY IGE, 2022-2030 (IN $ MILLION)
FIGURE 11: GLOBAL IMMUNOGLOBULIN MARKET, BY IGD, 2022-2030 (IN $ MILLION)
FIGURE 12: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY MODE OF DELIVERY, IN 2021
FIGURE 13: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)
FIGURE 14: GLOBAL IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)
FIGURE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)
FIGURE 16: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021
FIGURE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2030 (IN $ MILLION)
FIGURE 18: GLOBAL IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2030 (IN $ MILLION)
FIGURE 19: GLOBAL IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2030 (IN $ MILLION)
FIGURE 20: GLOBAL IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2030 (IN $ MILLION)
FIGURE 21: GLOBAL IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2030 (IN $ MILLION)
FIGURE 22: GLOBAL IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2030 (IN $ MILLION)
FIGURE 23: GLOBAL IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2030 (IN $ MILLION)
FIGURE 24: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2030 (IN $ MILLION)
FIGURE 25: GLOBAL IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2030 (IN $ MILLION)
FIGURE 26: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)
FIGURE 27: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2021
FIGURE 28: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2030 (IN $ MILLION)
FIGURE 29: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2030 (IN $ MILLION)
FIGURE 30: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER DISTRIBUTION CHANNELS, 2022-2030 (IN $ MILLION)
FIGURE 31: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
FIGURE 32: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)
FIGURE 33: GLOBAL IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2030 (IN $ MILLION)
FIGURE 34: NORTH AMERICA IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 35: UNITED STATES IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 36: CANADA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 37: EUROPE IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 38: UNITED KINGDOM IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 39: GERMANY IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 40: FRANCE IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 41: SPAIN IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 42: ITALY IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 43: NORDIC COUNTRIES IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 44: REST OF EUROPE IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 45: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 46: CHINA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 47: JAPAN IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 48: INDIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 49: SOUTH KOREA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 50: INDONESIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 51: THAILAND IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 52: VIETNAM IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 53: AUSTRALIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 54: REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 55: REST OF WORLD IMMUNOGLOBULIN MARKET, REGIONAL OUTLOOK, 2021 & 2030 (IN %)
FIGURE 56: LATIN AMERICA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)
FIGURE 57: MIDDLE EAST & AFRICA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)